Skip to main content

Table 1 Patient characteristics

From: 64Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients

Number Age (y) Histology IHC History of trastuzumab treatment Number of lesions ( φ <1 cm) detected by MRI/CT/ 64 Cu Number of lesions ( φ >1 cm) detected by MRI/CT/ 64 Cu
1 73 IDC-st 3+ Weekly 2/0/0 4/4/4
2 75 IDC-sc 3+ Weekly 0/0/0 1/0/1
3 65 IDC-sc 3+ Weekly 8/0/2 0/0/0
4 54 IDC-sc 3+ Tri-weekly 3/0/1 1/1/1
5 61 IDC-sc 3+ Weekly 0/0/0 1/1/1
  1. y, years; IDC-st, invasive ductal carcinoma-solid tubular; IDC-sc, invasive ductal carcinoma-scirrhous; 64Cu, 64Cu-DOTA-trastuzumab PET; Weekly, 2 mg/kg/week; Tri-weekly, 8 mg/kg/3 week.